Nuo Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Nov 12, 2024 and accepted by EDGAR at Nov 12, 2024, 13:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $371.0k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2024-01-01 to 2024-09-30 | $970.3k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2024-07-01 to 2024-09-30 | $100.5k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2024-01-01 to 2024-09-30 | $216.4k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-07-01 to 2024-09-30 | $270.4k | us-gaap:GrossProfit |
| Gross profit | 9 months2024-01-01 to 2024-09-30 | $753.9k | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2024-07-01 to 2024-09-30 | $847.8k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-01-01 to 2024-09-30 | $2.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | −$577.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-30 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2024-07-01 to 2024-09-30 | −$578.2k | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | −$1.8m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | −$1.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-01-01 to 2024-09-30 | $155.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-09-30 | $683.8k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $1.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $1.7m | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $714.0k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $828.7k | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-09-30 | $890.4k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-24-034325. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.